Clinical Research Trials

The following clinical trials are ongoing at the Lax Center and currently enrolling patients:

DISCOVER: GS-US-412-2055:  A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women who have Sex with Men and are at Risk of HIV-1 Infection
Beyond Antiretroviral Treatment: Reducing Proviral HIV DNA with Interferon-α Immunotherapy (BEAT-HIV): A randomized, multi-site, open-label study to assess the effectiveness of Peg-IFN-α2b in decreasing the levels of cell-associated, integrated viral DNA in HIV chronic infection
Merck Peripheral Blood Draw Study: A non-interventional trial intended to collect peripheral blood from patients undergoing treatment for chronic HIV infections

The following clinical trials are ongoing at the Lax Center but not enrolling new patients:

Title: Open Label, HIV/HCV Co-Infection study of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment in Subjects who Switch to Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Alafenamide
Trial Number: GS-US-366-1992
Description: A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co infected Subjects who Switch to Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) prior to LDV/SOF HCV Treatment, the HIV/HCV Co-STARs study (Co-infection treatment with Single Tablet Antiviral Regimens)
Title: Double-Blind Study to Evaluate Safety and Efficacy of GS-9883 versus Triumeq in HIV+, Treatment-Naïve Adults
Trial Number: GS-US-380-1489
Description: A Phase 3, randomized, double-blind study to evaluate the safety and efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 infected, antiretroviral treatment-naïve adults
Title: Double-Blind Study to Evaluate Safety and Efficacy of GS-9883 versus Tivicay plus F/TAF in HIV+, Treatment-Naïve Adults
Trial Number: GS-US-380-1490
Description: A Phase 3, randomized, double-blind study to evaluate the safety and efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 infected, antiretroviral treatment-naïve adult
Title: Double-Blind Study to Evaluate the Safety and Efficacy of Switching from Dolutegravir and ABC/3TC (or a Fixed-Dose Combination of ABC/DTG/3TC) to a Fixed-Dose Combination of GS-9883/F/TAF
Trial Number: GS-US-380-1844
Description: A Phase 3, randomized, double-blind study to evaluate the safety and efficacy of switching from a regimen of Dolutegravir and ABC/3TC, or a fixed-dose combination (FDC) of ABC/DTG/3TC,  to a FDC of GS-9883/F/TAF in HIV-1 infected subjects who are virologically suppressed
Title: Double-Blind Switch Study to Evaluate F.TAF in HIV-1 Infected Subjects who are Virologically Suppressed
Trial Number: Protocol GS-US-311-1717
Description: A Phase 3b, randomized, double-blind, switch study to evaluate F/TAF in HIV-1 infected subjects who are virologically suppressed on regimens containing ABC/3TC
Title: Switch Study to Evaluate D/C/F/TAF, Once-Daily versus Staying on a Boosted Protease Inhibitor Regimen
Trial Number: TMC114IFD3013
Description: A Phase 3, randomized, active-controlled, open-label study to evaluate switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once-daily, single-tablet regimen versus continuing the current regimen consisting of a boodted protease inhibitor (bPI) combined with emtricitabine/tenofovir disproxil fumerate (FTC/TDF) in virologically-suppressed, human immunodeficiency virus, type-1 (HIV-1) infected subjects
Title: Hepatitis C Treatment SVR Registry
Trial Number: GS-US-248-0122
Description: A long term follow-up registry for subjects who achieve a sustained virologic response to treatment in gilead-sponsored trials in subjects with Chronic Hepatitis C infection (rollover study).
Title: Clinical Evaluation of Xpert HIV Viral Load Assay
Trial Number: 177b
Description: Sponsored by Cepheid
Title: The Immunopathogenisis of HIV
Description: Sponsored by The Wistar Institute

The following clinical trials are ongoing at the YHEP Youth Health Center and currently enrolling patients:

There are currently no open an enrolling trials at YHEP Health Center. Please check back soon for updated information.


The following clinical trials are ongoing at the YHEP Youth Health Center but not enrolling new patients:

Prevalence of a Mental Health Diagnosis or Experience of Childhood Trauma in Youth Taking PrEP
Note: subjects eligible during participation in the GS-US-276-1295 trial

For more information on any of the clinical trials listed, please contact the Research Department at 215-525-8695.